Join our daily newsletter At The Bell to receive exclusive market insights
- Volpara Health Technologies (VHT) has signed its highest value contract to date though recently acquired subsidiary CRA Health
- The contract is worth over US$400,000 (roughly A$513,000) per year in annual recurring revenue
- The contract covers the provision of breast cancer risk scores to a large Indiana-based organisation that has sites across more than 20 U.S. states
- Volpara’s CEO says the contract will enable VHT to help more women across the United States benefit from early cancer detection and sets the company up for future sales of additional products
- Volpara Health Technology is up 7.22 per cent, trading at $1.41
Volpara Health Technologies (VHT) has signed its highest value contract to date though recently acquired subsidiary CRA Health.
Volpara forked out over $23 million to buy Boston-based breast cancer risk assessment company CRA Health in February this year.
The purchase gave Volpara access to CRA’s cloud-based breast cancer assessment software, which the company considered to be highly complementary to Volpara’s own medical breast imaging and analytics technology.
The contract, worth over US$400,000 (roughly A$513,000) per year in annual recurring revenue, covers the provision of breast cancer risk scores to a large Indiana-based organisation that has sites across more than 20 U.S. states.
The unnamed organisation also runs a major electronic health record system.
“We are very pleased to announce that CRA Health has signed up a major US health system with significant ARR associated with it,” said Volpara Group CEO, Dr Ralph Highnam.
“Whilst we would not normally announce individual deals, this is the Volpara Group’s highest value contract signed to date. Not only does it enable us to help many more women across the United States benefit from early cancer detection, but it also sets us up for future sales of additional products to this organisation.”
“Further, the contract is validation of the decision to purchase CRA Health and validation that the world is rapidly moving towards personalised breast care, which includes analysis of risk and genetics.”
Volpara Health Technology is up 7.22 per cent, trading at $1.41 at 12:30 pm AEDT.
